Arix Bioscience Share Discussion Threads

[hpcg] 27/6/2022 11:04

I've seen some people calling the bottom in XBI too. I don't know, on a 5 year chart it looks like a firm line of support, but on the other hand it benefits from, and requires, risk capital more than any other sector.

[ohisay] 09/6/2022 09:25

Yes good to see the cash backing spelt out . They should have done the monthly NAV reporting a long time ago ..arguably share price would not be quite as low as it is if they'd done it earlier. Of course Biotech in the US hasnt done at all well since the beginning of last year: though I see a lot of suggestions recently suggesting its bottomed out. I've added a few of these (Arix) as they seem to have changed tack recently in going for semi established companies rather than IPO's. https://seekingalpha.com/symbol/XBI/charting?axis=percentage&compare=XBI,SP500TR,PPH&interval=1Y&metric=priceReturn&series=line

[spectoacc] 09/6/2022 08:42

I like the clear way ARIX are now presenting the NAV - be good if that was taken up by others, rather than just the "NAV: 177p".

[jay083] 31/5/2022 11:40

https://www.ft.com/content/1854f495-1138-42f5-aa57-3ec52d782bbd#comments-anchor Interesting piece on biotech in general

[spectoacc] 31/5/2022 10:20

Been a decent biotech rally (or dcb more likely). ARIX has singularly failed to partake in it.

[spectoacc] 10/5/2022 08:42

Short-term impact perhaps. I'd usually sell into any ST tip or comment, but not this time, nothing to realise yet ;)

[value hound] 10/5/2022 08:40

I think the mkt cap is too big for Simon T's tip to have a real impact; much larger than most of his others.

[ohisay] 10/5/2022 08:36

Yes I think the Artios holding keeps him hopeful. https://www.investorschronicle.co.uk/ideas/2022/05/09/bargain-shares-a-ben-graham-contrarian-value-play/ Moreover, it’s not as if the unlisted holdings are worthless. Half that portfolio is invested in Artios, a leading DNA Damage Response (DDR) company that is developing a pipeline of precision medicines for the treatment of cancer. Artios has a research collaboration with drug giant Novartis to discover and validate next-generation DDR targets to enhance Novartis' Radioligand Therapies. I have great hopes for Artios (‘Five investment company bargains’ 8 April 2021). Large pharmaceutical companies have historically outsourced much of the research and development of new drugs to smaller companies, often start-ups, which are faster and more agile in making cutting-edge medical breakthroughs. Bearing this in mind, analysts forecast that big US and European pharma groups could have $500bn to deploy on acquisitions in the coming years, providing a clear path to exit for biotech companies that do succeed. Arix’s diversified portfolio offers such exposure

[frazboy] 09/5/2022 18:34

An ST tip isn't having its usual impact at the moment! In saying that I realise he's been a fan of this for a while.

[mirabeau] 09/5/2022 18:03

Tipped by ST in IC

[snappler] 06/5/2022 07:21

The best Case for the investors is, if they make a Tender offer similar to Malin Corp and repurchase a large amount of outstanding shares at NAV.

[ohisay] 05/5/2022 09:20

This is a good move ..I hope they do more of it . There are plenty of established undervalued Pharma stocks around atm. Following market purchases since 31 December 2021, Arix has a new holding in each of the companies listed below: Listed on Nasdaq No. of shares Cost GBP Percentage ownership Black Diamond Therapeutics Inc. 481,900 1,482,061 1.3% Bolt Bio Therapeutics Inc. 118,500 330,367 0.3% Cullinan Oncology Inc. 66,500 556,615 0.2% Dyne Therapeutics Inc. 155,100 866,838 0.3% Edgewise Therapeutics Inc. 50,200 313,732 0.1% Inozyme Pharma Inc. 151,006 652,894 0.6% Kinnate Biopharma Inc. 190,000 1,495,868 0.4% Kronos Bio Inc 149,000 808,931 0.3% Olema Pharmaceuticals Inc. 610,000 2,521,731 1.5% Prelude Therapeutics Inc. 150,000 1,158,895 0.3% Silverback Therapeutics Inc. 470,300 1,598,857 1.3% TCR2 Therapeutics Inc. 465,000 1,114,384 1.2% At the start of 2022, we began investing in a Public Opportunities Portfolio of listed biotechnology stocks which we believe are undervalued, having carefully assessed their clinical programmes and potential. Initially comprised of ten companies with a total investment of around 5% of our NAV, the individual positions are small enough to be easily liquidated and will be actively managed in response to market movements. .

[lennonsalive] 05/5/2022 07:50

I did say this at the time

[pinemartin9] 05/5/2022 07:22

Hmmmm...that shareback was a car crash. Not sure what to make of it here really. The NAV drop is not surprising really. I need to assess whether my initial investment case holds true. For me this was always about getting exposure to high risk Biotech start ups which it does. Will be interesting to see how we fare today!

[daemonfunds] 04/5/2022 22:56

My guess: they're going to ask the board to return all cash that hasn't been pledged and to liquidate all listed holdings and will ask them to reduce admin expenses run down the portfolio of unlisted portfolio holdings. That way they get their money back immediately, which can be redeployed elsewhere, and are left with free options that play out over time.

[weatherman] 04/5/2022 22:18

hxxps://news.sky.com/story/biotech-group-arix-prepares-board-shake-up-in-peace-deal-with-activist-acacia-12284005 Is Woodward still advising Acacia and planning a comeback? - this was from last year.

[lennonsalive] 04/5/2022 20:03

So, no offer. Results this week?

[hugepants] 04/5/2022 11:55

This Acacia outfit have been putting pressure on the Board. Good to see them increasing to over 21%.

[mirabeau] 04/5/2022 07:27

Overview Acacia Research seeks to acquire undervalued businesses with a primary focus on mature technology, life sciences, industrial and certain financial services segments, and pursues opportunities for value creation that leverage Acacia’s significant capital resources as well as its expertise in corporate governance and operational restructuring.

[weatherman] 04/5/2022 07:08

Could we be looking at a bid for the company by Merton Acquisition Holdco LLC? - they seem to have increased their stake.

[ohisay] 30/4/2022 05:38

Arix intends to provide regular market updates on its unaudited NAV and is therefore today also releasing its position as of 31 March 2022. The penny has finally dropped !.. 31-Mar-22 Listed GBP53.5m /Unlisted BP57.2m / Cash etc GBP130.6m /Total GBP241.3m /1.87p per share. So cash etc of 101p per share. So at 114p per share current price ..the listed/unlisteds are effectively discounted by 85% if my maths is right . And cash is 89% of the share price .

[eaaxs06] 29/4/2022 12:04

Better late than never, those numbers are much higher than I was expecting. I'm sure Mr Thompson will have something to say about them next week. Good luck everyone, Sid.

[novision] 29/4/2022 11:22

NAV Update 187p / share...

[novision] 24/4/2022 10:40

Had this message when I emailed them 5/4/22.... Thank you for your email. We are aiming towards the end of this month although the date is still to be confirmed. Please look out for a press release over the coming weeks with the date and webcast links.